Pharma Update
RG6179: Novel anti-IL-6 mAb for intraocular use
New data investigating anti-IL-6 in uveitic macular edema shared at ARVO 2023
Anti-IL-6 mAb
Uveitic macular edema
IL-6
OCT scan: healthy macular
IL-6
Roche
OARVO.
Ph I data (DOVETAIL) presented at ARVO 20231
Change from baseline in BCVA
Fc region
OCT scan: macular edema
Mean (SE) change from baseline in
BCVA (letters)
15- Treatment phase
10-
2
8
Weeks
Off-treatment phase
0.25 mg
1mg
12
2.5mg
16
20
•
Anti-IL-6 mAb binds IL-6 and
inhibits all known forms of IL-6
signaling
•
Specifically designed for
intraocular use and optimized for
a rapid systemic clearance
UME is a common result of
intraocular inflammation, with only
limited treatment options
Inflammation causes vascular
leakage & fluid accumulation within
the retina²
Preliminary clinical data in UME indicating:
•
.
•
Improved vision and absence of retinal fluid in all dosing cohorts
25-36% of patients gained 15 letters or more at week 12
All doses of anti-IL-6 were well tolerated across all patients, with
no treatment-related serious AEs, sustained IOP increase, or new
cataracts
Based on these Ph I findings, a Ph III clinical trial program is ongoing
1. Sharma et al. ARVO 2023; 2. Koronis et al. Drug Des Devel Ther. 2019 Feb 19;13:667-680. doi: 10.2147/DDDT.S166092; UME=uveitic macular edema; IOP=intraocular pressure; IL-6=interleukin-6; AE=Adverse event;
BCVA-Best-corrected visual acuity; SE-Standard error; OCT-Optical coherence tomography; mAb=Monoclonal antibody
125View entire presentation